Kelly Brian P, Paterson Wendy F, Donaldson Malcolm D C
Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, Scotland, UK.
Clin Endocrinol (Oxf). 2003 Mar;58(3):267-72. doi: 10.1046/j.1365-2265.2003.01692.x.
Constitutional delay in growth and adolescence (CDGA) is common in boys, some of whom request treatment to accelerate growth and attainment of secondary sexual characteristics. The aims of this study were to confirm that a 3-month course of intramuscular testosterone oenanthate does not impair final height in boys with CDGA, and to determine the accuracy of height prediction in this condition.
Boys with CDGA who had attended the growth clinic, who were now at or close to final height and who had received either testosterone or declined treatment, were identified by retrospective case note analysis. Bone age assessment was carried out by a single observer, using the RUS (TW2) method of Tanner and Whitehouse.
The following auxological data were extracted from the case records: age, bone age, height, pubertal stage, parental heights and predicted final height. All subjects were then measured at age 19 years or greater. The main outcome measures were comparison of final height in treated and untreated boys; final height comparison with mid-parental height and with height prediction [RUS (TW2) method] at initial assessment and at subsequent review.
Sixty-four boys met the inclusion criteria, of whom 41 subjects had received testosterone and 23 were untreated. There were no significant differences between the groups (treated mean/SD vs. untreated mean/SD; P-value) in age (14.3/0.7 vs. 14.0/1.1; 0.13), height (144.7/6.2 vs. 144.2/6.2; 0.79), mid-parental heights (170.4/5.5 vs. 171.1/4.5; 0.59), and bone age (12.0/1.2 vs. 12.3/1.3; 0.36). Final heights in both groups (168.9/6.0 vs. 168.2/3.5; 0.65) were closely related to predicted final heights (170.0/5.0 vs. 168.1/4.1; 0.15) and only slightly less than mid-parental heights. Only three subjects had final heights below the initial height prediction range.
Our data support the hypothesis that this treatment regime does not adversely affect the final height achieved in constitutional delay of growth and adolescence and that height prediction, assessed by a single observer, is a useful and accurate tool.
体质性生长和青春期延迟（CDGA）在男孩中很常见，其中一些人要求治疗以加速生长和第二性征的发育。本研究的目的是证实三个月的庚酸睾酮肌肉注射疗程不会损害CDGA男孩的最终身高，并确定这种情况下身高预测的准确性。
通过回顾性病例记录分析，确定曾就诊于生长诊所、现已达到或接近最终身高、接受过睾酮治疗或拒绝治疗的CDGA男孩。骨龄评估由一名观察者采用Tanner和Whitehouse的RUS（TW2）方法进行。
从病例记录中提取以下人体测量学数据：年龄、骨龄、身高、青春期阶段、父母身高和预测的最终身高。然后对所有受试者在19岁及以上时进行测量。主要结局指标为比较接受治疗和未接受治疗男孩的最终身高；将最终身高与父母平均身高以及初始评估和后续复查时的身高预测值[RUS（TW2）方法]进行比较。
64名男孩符合纳入标准，其中41名受试者接受了睾酮治疗，23名未接受治疗。两组在年龄（14.3/0.7 vs. 14.0/1.1；P值0.13）、身高（144.7/6.2 vs. 144.2/6.2；P值0.79）、父母平均身高（170.4/5.5 vs. 171.1/4.5；P值0.59）和骨龄（12.0/1.2 vs. 12.3/1.3；P值0.36）方面无显著差异。两组的最终身高（168.9/6.0 vs. 168.2/3.5；P值0.65）与预测的最终身高密切相关（170.0/5.0 vs. 168.1/4.1；P值0.15），且仅略低于父母平均身高。只有三名受试者的最终身高低于初始身高预测范围。
我们的数据支持以下假设，即这种治疗方案不会对体质性生长和青春期延迟所达到的最终身高产生不利影响，并且由一名观察者评估的身高预测是一种有用且准确的工具。
